Stifel Financial Corp Has $15.62 Million Stock Position in Omeros Co. (NASDAQ:OMER)

Stifel Financial Corp reduced its stake in shares of Omeros Co. (NASDAQ:OMER - Free Report) by 17.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,581,205 shares of the biopharmaceutical company's stock after selling 323,002 shares during the quarter. Stifel Financial Corp owned 2.73% of Omeros worth $15,622,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in OMER. Tower Research Capital LLC TRC increased its holdings in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 1,972 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Omeros in the 4th quarter valued at approximately $437,000. XTX Topco Ltd acquired a new position in Omeros during the fourth quarter valued at approximately $206,000. Barclays PLC increased its stake in Omeros by 9.6% in the fourth quarter. Barclays PLC now owns 103,726 shares of the biopharmaceutical company's stock valued at $1,025,000 after purchasing an additional 9,086 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Omeros during the 4th quarter worth $124,000. Institutional investors and hedge funds own 48.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on OMER shares. StockNews.com lowered shares of Omeros from a "hold" rating to a "sell" rating in a research note on Wednesday, April 9th. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research note on Tuesday, April 1st. Finally, D. Boral Capital restated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research note on Friday, April 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.50.

Omeros Trading Down 0.4 %

Shares of NASDAQ:OMER traded down $0.03 during trading on Friday, reaching $6.99. 163,590 shares of the stock were exchanged, compared to its average volume of 580,807. The firm has a market cap of $405.93 million, a PE ratio of -3.02 and a beta of 2.35. Omeros Co. has a 12 month low of $3.00 and a 12 month high of $13.60. The stock has a 50-day moving average price of $7.66 and a 200-day moving average price of $8.03.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.08. During the same period in the prior year, the firm posted ($0.15) EPS. On average, sell-side analysts expect that Omeros Co. will post -3.09 earnings per share for the current fiscal year.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.